JB Pharma records 12 per cent revenue growth in Q1
Synopsis. JB Pharma, led by CEO Nikhil Chopra, forecasts 12-14% revenue growth and aims to increase Ebitda margins by 27-28% in FY25. The growth is driven by a focus on chronic portfolio, CDMO business expansion, and upcoming acquisition of an ophthalmology drugs portfolio from Novartis
JB Pharma acquires trademark licenses, distribution rights of Novartis eye care portfolio in India for Rs 1089 crore
JB Pharma open to more buys to grow branded biz share
This Doctor’s Day, JB Pharma introduced JB NEXT, app exclusively designed for resident doctors & post-graduate medical students. The app is an expression of gratitude to the medical fraternity with its comprehensive and multi-speciality specific content and resources to enhance their knowledge.
JB Pharma, the fastest growing company in the Indian pharmaceutical market, marks the one-year anniversary of the launch of their identity. Good People for Good Health is a testament of the brands unwavering commitment to spreading good health globally. Crossing the milestone, the company highlights their- journey of contributions made towards Indian healthcare – of supporting healthcare providers and enriching patients’ lives globally. This is reflected in three key elements which are – their people, products, and financial results.
JB Chemicals & Pharmaceuticals (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced its financial results for the fourth quarter and year ended 31st March, 2022.
JB Chemicals & Pharmaceuticals ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced record revenue growth of 32% to Rs. 793 crore in Q3 FY23.
JB Pharma on Wednesday said it has acquired cardiac brand Razel (rosuvastatin) for India and Nepal region from Glenmark for Rs 314 crore in an all-cash deal. The acquisition will be funded through long-term debt and internal accruals, the KKR-backed company said in a statement.
JB Pharma on Monday announced a 50% price cut for its heart failure drug Azmarda, which is a sacubitril-valsartan combination, in anticipation of stiff competition with the drug going off-patent in January 2023.